Among these, glucagon-like peptide-1 receptor agonists (GLP1RAs) have attracted particular attention for their profound effects on body weight, glycemic control, and cardiovascular outcomes [4,5] , which extend beyond metabolic effects [4] , alongside emerging evidence of liver-specific benefits [5,6]
BPC 157 is also an anti-inflammatory agent that has been shown to have clinical relevance in patients with congestive heart failure
The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: results from STOP trial
Read More Blog Ultherapy vs
Ipamorelins selectivity rests on foundational pharmacology : mechanism-defining work that is robust for what it claims (a clean GH-secretagogue profile) but is not an efficacy trial for any body-composition endpoint
Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database